WO2002024625A2 - Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives - Google Patents

Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives Download PDF

Info

Publication number
WO2002024625A2
WO2002024625A2 PCT/IB2001/001699 IB0101699W WO0224625A2 WO 2002024625 A2 WO2002024625 A2 WO 2002024625A2 IB 0101699 W IB0101699 W IB 0101699W WO 0224625 A2 WO0224625 A2 WO 0224625A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
alkyl group
acid
lower alkyl
Prior art date
Application number
PCT/IB2001/001699
Other languages
French (fr)
Other versions
WO2002024625A3 (en
Inventor
Rajender Kumar Potlapally
Mahender Rao Siripragada
Narasimha Murthy Kotra
Raju Sirisilla
Ramabhadra Sarma Mamillapalli
Om Reddy Gaddam
Original Assignee
Dr. Reddy's Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/836,559 external-priority patent/US6559335B2/en
Application filed by Dr. Reddy's Research Foundation filed Critical Dr. Reddy's Research Foundation
Priority to AU2001286163A priority Critical patent/AU2001286163A1/en
Publication of WO2002024625A2 publication Critical patent/WO2002024625A2/en
Publication of WO2002024625A3 publication Critical patent/WO2002024625A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/10Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/10Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C07C67/11Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups

Definitions

  • the present invention relates to an improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1)
  • R represents hydrogen atom or (C]-C 6 )alkyl group and R 2 represents (C ⁇ -C 6 )alkyl group.
  • the compound of formula (1) is useful as an intennediate for the preparation of many pharmaceutically active compounds.
  • 3-Aryl-2-hydroxy propanoic acid derivatives are also used as sweetening agent (Gries etal. EP 55,689 (1982)), also in photosensitive materials ( Komamura etal. JP 6022850) and also in liquid crystals (Grey et.al.
  • WO 88/02390 It is also a part of sesquiterpene lactone glycoside isolated from Crepis tectorium (Kisiel Wanda etal. Phytochemistry, 2403, 28 (9) (1989)]. It is also part of Aeruginorins 102 A and B, a new class of Thrombin inhibitors from the Cyanobacterium Microcystis vindis.
  • 3-Aryl-2-hydroxy propanoic acid is prepared by several methods reported in the literature. Hisashi Matruda. etal., Tet. 52 (46) 14501 (1996)
  • the compound of formula (7) is produced in racemic mixture, which has to be resolved to get the optically pure material.
  • WO 99/62872 and WO01/40159 describes a process for the preparation of. compound of formula (I), wherein R 2 is OH or the group OR p , where in R p is protecting group consisting of H, benzyl or (CrC 3 )alkyl, which comprises reacting a racemic compound of the formula II where Q is a protecting group or H, with a chiral amine forming a salt of the formula ' III, subsequently separating the diastereomers by crystallization followed by removal of the amine and deprotecting the Q group of the resulting compound with a deprotecting agents and optionally protecting a free carboxylic acid function with the group R .
  • the reaction is shown in scheme 5 below :
  • the main objective of the present invention is to provide a simple and robust process for the preparation of the compound of formula (1) with high chemical and chiral purity.
  • Another objective of the present invention is to produce pure and stable compound of formula (9) acid salt with respect to chemical and chiral purities.
  • the present invention provides an improved process for the preparation 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1)
  • R 1 represents hydrogen atom or (C r C 6 )alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl and the like
  • R represents (Cj- C 6 )alkyl group such as methyl, ethyl, propyl, isopropyl and the like which comprises:
  • Scheme-6 The process of the present invention starts with benzylating the compound formula (14) using benzyl halide such as benzyl chloride, benzyl bromide and the like, CuSO , sodium hydroxide in the presence of solvents such as aqueous methanol, ethanol and the like to afford compound of the formula (15).
  • benzyl halide such as benzyl chloride, benzyl bromide and the like
  • CuSO sodium hydroxide
  • solvents such as aqueous methanol, ethanol and the like
  • diazotizing agent such as sodium nitrite, isoamyl nitrite, potassium nitrite, ammonium nitrite and the like
  • acids such as sulfuric acid, HC1, acetic acid and the like
  • organic solvent such as CHC1 3 , 1,4-dioxane, THF, acetone and the like
  • Simultaneous etherification and esterification of compound of formula (8a) to obtain crude compound of formula (9) may be carried out using alkyl sulfates such as diethyl sulphate, dimethylsulphate and the like or alkyl halides such as ethyl iodide, methyliodide and the like, in the presence of solvents such as hydrocarbons like toluene, benzene and the like or DMF, DMSO, methyl isobutyl ketone (MIBK) and the like, in alkali bases such as sodium carbonate, potassium carbonate, sodium methoxide, sodium hydride and the like.
  • alkyl sulfates such as diethyl sulphate, dimethylsulphate and the like or alkyl halides such as ethyl iodide, methyliodide and the like
  • the compound of formula (9) may also be prepared by slow addition of compound of formula (8a) to a solution of DMF, sodium hydride, and alkali halides such as methyl iodide, ethyl iodide and the like at a temperature ranging from 0 to 80 °C.
  • alkali halides such as methyl iodide, ethyl iodide and the like at a temperature ranging from 0 to 80 °C.
  • the compound of formula (9) upon hydrolysis in polar solvents like alcohols such as methanol, ethanol, propanol, isopropanol and the like or ketonic solvents such as acetone, methyl ethyl ketone and the like using aqueous alkali base such as sodium hydroxide or potassium hydroxide yields compound of formula (9a).
  • the compound of formula (16) defined above may further purified by recrystallization from solvents such as alkyl ester such as methyl acetate, ethyl acetate, ethyl propanoate, n-butylacetate and the like or alcohol such as methanol, ethanol, propanol, isopropanol and the like or ketone such as acetone, methyl ethyl ketone, methyl isobutyl ketone and the like or acetonitrile to obtain highly pure compound of formula (16).
  • solvents such as alkyl ester such as methyl acetate, ethyl acetate, ethyl propanoate, n-butylacetate and the like or alcohol such as methanol, ethanol, propanol, isopropanol and the like or ketone such as acetone, methyl ethyl ketone, methyl isobutyl ketone and the like or acetonitrile to
  • the pure compound of formula (9a) is obtained from the compound of formula (16) by treating with acid such as hydrochloric acid, sulfuric acid and the like in the presence of solvent such as toluene, xylene, ethyl acetate, diethyl ether, methyl tertiary butyl ether and the like.
  • acid such as hydrochloric acid, sulfuric acid and the like
  • solvent such as toluene, xylene, ethyl acetate, diethyl ether, methyl tertiary butyl ether and the like.
  • the pure compound of formula (9a) obtained above is esterified with suitable alcohols such as methanol, ethanol, propanol, isopropanol, butanol and the like or alkyl sulfates such as methyl sulfate, ethyl sulfate and the like in the presence of acids such as hydrochloric acid, sulfuric acid and the like or acidic resins such as amberlite, amberlist and the like or bases such as potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate or organic bases such as alkoxides like sodium ethoxide, potassium tertiary butoxide or triethyl amine and the like to produce pure compound of formula (9).
  • suitable alcohols such as methanol, ethanol, propanol, isopropanol, butanol and the like or alkyl sulfates such as methyl sulfate, ethyl sulfate and the like in the presence of acids such as hydro

Abstract

The present invention relates to an improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives of formula (1) where R1 represents hydrogen atom or (C¿1?-C6)alkyl group and R?2¿ represents (C¿1?-C6)alkyl group which comprises: (i) selectively benzylating L-tyrosine to yield compound of formula (15); (ii). diazotising the compound of formula (15) to produce compound of formula (8); (iii) simultaneous etherification and esterification of compound of formula (8) to obtain crude compound of formula (9) with ee>90 %; (iv) hydrolysing the crude compound of formula (9) to produce compound of formula (9a) acid; (v) treating the compound of formula (9a) with chiral base to produce pure salt of formula (16); (vi) converting the compound of formula (16) to pure compound of formula (9a); (vii) esterifying pure compound of formula (9a) to produce pure compound of formula (9); (viii) debenzylating the compound of formula (9) to yield pure compound of formula (1).

Description

AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARY -2- HYDROXY PROPANOIC ACID DERTVATIVES
Field of the invention
The present invention relates to an improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1)
Figure imgf000002_0001
wherein R represents hydrogen atom or (C]-C6)alkyl group and R2 represents (Cι-C6)alkyl group.
The compound of formula (1) is useful as an intennediate for the preparation of many pharmaceutically active compounds.
Background of invention The process for the preparation of 3-aryl-2-hydroxy propanoic acid, its derivatives and analogs exhibiting various pharmacological actives have been described in US 5,232,945, US 5,306^726, WO 91/11999, DE 1,948,373, DE. 2,033,959, DE 2,014,479, DE 1,668,938, WO 91/19702, WO 92/0252, WO 96/04260, WO 96/0426, WO 95/17394. In addition, these compounds are considered to be useful for treating certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with eating such as anorexia nervosa and disorders associated with overeating such as obesity and anorexia bulimia.
3-Aryl-2-hydroxy propanoic acid derivatives are also used as sweetening agent (Gries etal. EP 55,689 (1982)), also in photosensitive materials (Komamura etal. JP 6022850) and also in liquid crystals (Grey et.al.
WO 88/02390). It is also a part of sesquiterpene lactone glycoside isolated from Crepis tectorium (Kisiel Wanda etal. Phytochemistry, 2403, 28 (9) (1989)]. It is also part of Aeruginorins 102 A and B, a new class of Thrombin inhibitors from the Cyanobacterium Microcystis vindis.
3-Aryl-2-hydroxy propanoic acid is prepared by several methods reported in the literature. Hisashi Matruda. etal., Tet. 52 (46) 14501 (1996)
HzN
Figure imgf000003_0001
(2) (3) Scheme-1
In our WO publication No. 00/26200 we have described process for preparing the compound of formula (1). The reaction schemes are shown below :
Figure imgf000003_0002
(1) (9) (8)
Scheme-2 u'
Though it is convergent synthetic method, the compound of formula (7) is produced in racemic mixture, which has to be resolved to get the optically pure material.
Figure imgf000004_0001
ScSιeme-3 In this process too the resolution has to be carried out for compound of formula (7).
Figure imgf000004_0002
(9)
Scheme-4
WO 99/62872 and WO01/40159 describes a process for the preparation of. compound of formula (I), wherein R2 is OH or the group ORp, where in Rp is protecting group consisting of H, benzyl or (CrC3)alkyl, which comprises reacting a racemic compound of the formula II where Q is a protecting group or H, with a chiral amine forming a salt of the formula ' III, subsequently separating the diastereomers by crystallization followed by removal of the amine and deprotecting the Q group of the resulting compound with a deprotecting agents and optionally protecting a free carboxylic acid function with the group R . The reaction is shown in scheme 5 below :
Figure imgf000005_0001
Scheme-5
Objective of present invention The main objective of the present invention is to provide a simple and robust process for the preparation of the compound of formula (1) with high chemical and chiral purity. Another objective of the present invention is to produce pure and stable compound of formula (9) acid salt with respect to chemical and chiral purities.
To convert the crude compound of formula (9) (partially racemised) to compound of formula (9) acid and to get pure compound of formula (9) acid, which is back esterifϊed to get pure compound of formula (9). To overcome the problem of partial racemisation during the conversion of compound of formula (8) to compound of formula (9).
To avoid use of highly reactive, difficult to handle and expensive chemicals such as sodium hydride and ethyl iodide and replaced with simple, inexpensive chemicals such as diethylsulphate and potassium carbonate.
Detailed description of the invention
Accordingly, the present invention provides an improved process for the preparation 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1)
Figure imgf000005_0002
wherein R1 represents hydrogen atom or (CrC6)alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl and the like, and R represents (Cj- C6)alkyl group such as methyl, ethyl, propyl, isopropyl and the like which comprises:
(i). selectively benzylating L-tyrosine of the formula (14) using benzyl halide, CuSO and sodium hydroxide in a solvent to yield a compound of the formula (15),
(ii). diazotising the compound of the formula (15) using diazotizing agent in the presence of an acidic reagent and an organic solvent to produce compound of the formula (8a), (iii). simultaneous etheriiϊcation and esterifϊcation of compound of formula (8a) using allcylating agent in the presence of a base and a solvent to obtain crude compound of formula (9) with ee >90 % wherein R1 represents hydrogen or lower alkyl group and R represents lower alkyl group., (iv). hydrolysing the crude compound of formula (9) obtained in step (iii) above in polar solvents using aqueous alkali to produce compound of formula (9a) acid wherein R1 represents hydrogen or lower alkyl group,
(v). treating the compound of formula (9a) acid where R1 represents hydrogen and lower alkyl group with chiral base in the presence of solvent to produce chemical and chiral pure (ee >99 %) salt of formula (16) where R1 represents hydrogen or lower alkyl group and X represents chiral bases such as R(+)-α-methylbenzylamine, S(+) phenylglycinol, cinchonidine, ephidrine, N- octylglucaramine, N-methylglucaramine and the like,
(vi). if desired, recrystallizing the compound of formula (16) obtained above in. a solvent to produce highly pure compound of formula (16) where R1 represents hydrogen or lower alkyl group, (vii). converting the compound of formula (16) defined above using a solvent and an acid to pure compound of formula (9a) where R1 represents hydrogen or lower alkyl group,
(viii). esterifying the pure compound of formula (9a) defined above using alkylating agent in the presence of base or acid or acidic resin to produce pure compound of formula (9) where R1 represents hydrogen or lower alkyl group and R2 represents lower alkyl group and
(ix). debenzylating the compound of formula (9) using solvents in the presence of metal catalysts to yield pure compound of formula (1) where R1 represents hydrogen or lower alkyl group and R2 represents lower alkyl group.
The process explained above is shown in scheme-6 below
Figure imgf000007_0001
Scheme-6 The process of the present invention starts with benzylating the compound formula (14) using benzyl halide such as benzyl chloride, benzyl bromide and the like, CuSO , sodium hydroxide in the presence of solvents such as aqueous methanol, ethanol and the like to afford compound of the formula (15). Diazotization of the compound of the formula (15) using diazotizing agent such as sodium nitrite, isoamyl nitrite, potassium nitrite, ammonium nitrite and the like under acidic conditions using acids such as sulfuric acid, HC1, acetic acid and the like, in an organic solvent such as CHC13, 1,4-dioxane, THF, acetone and the like, gives the compound of the formula (8a). Simultaneous etherification and esterification of compound of formula (8a) to obtain crude compound of formula (9) may be carried out using alkyl sulfates such as diethyl sulphate, dimethylsulphate and the like or alkyl halides such as ethyl iodide, methyliodide and the like, in the presence of solvents such as hydrocarbons like toluene, benzene and the like or DMF, DMSO, methyl isobutyl ketone (MIBK) and the like, in alkali bases such as sodium carbonate, potassium carbonate, sodium methoxide, sodium hydride and the like. Alternatively, the compound of formula (9) may also be prepared by slow addition of compound of formula (8a) to a solution of DMF, sodium hydride, and alkali halides such as methyl iodide, ethyl iodide and the like at a temperature ranging from 0 to 80 °C. The compound of formula (9) upon hydrolysis in polar solvents like alcohols such as methanol, ethanol, propanol, isopropanol and the like or ketonic solvents such as acetone, methyl ethyl ketone and the like using aqueous alkali base such as sodium hydroxide or potassium hydroxide yields compound of formula (9a). The resolution of compound of formula (9a) with chiral base such as R(+)-α- methylbenzylamine, S(+) phenylglycinol, cinchonidine, ephidrine, N- octylglucaramine, N-methylglucaramine and the like using solvents such as alkyl ester such as methyl acetate, ethyl acetate, ethyl propanoate, n- butylacetate and the like or alcohol such as methanol, ethanol, propanol, isopropanol and the like or ketone such as acetone, methyl isobutyl ketone and the like or acetonitrile produces the chemical and chiral pure compound of formula (16) where " X represents chiral base such as R(+)-α- methylbenzylamine, S(+) phenylglycinol, cinchonidine, ephidrin, N- octylglucaramine, N-methylglucaramine and the like. The compound of formula (16) defined above may further purified by recrystallization from solvents such as alkyl ester such as methyl acetate, ethyl acetate, ethyl propanoate, n-butylacetate and the like or alcohol such as methanol, ethanol, propanol, isopropanol and the like or ketone such as acetone, methyl ethyl ketone, methyl isobutyl ketone and the like or acetonitrile to obtain highly pure compound of formula (16). The pure compound of formula (9a) is obtained from the compound of formula (16) by treating with acid such as hydrochloric acid, sulfuric acid and the like in the presence of solvent such as toluene, xylene, ethyl acetate, diethyl ether, methyl tertiary butyl ether and the like. The pure compound of formula (9a) obtained above is esterified with suitable alcohols such as methanol, ethanol, propanol, isopropanol, butanol and the like or alkyl sulfates such as methyl sulfate, ethyl sulfate and the like in the presence of acids such as hydrochloric acid, sulfuric acid and the like or acidic resins such as amberlite, amberlist and the like or bases such as potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate or organic bases such as alkoxides like sodium ethoxide, potassium tertiary butoxide or triethyl amine and the like to produce pure compound of formula (9). The debenzylation of the compound of formula (9) using THF, aqueous acetic acid, ethyl acetate, aqueous or non aqueous (Cι-C ) alcohols such as methanol, ethanol, propanol, isopropanol and the like in the presence of metal catalysts such as Pd/C produces pure compound of formula (1).
It is appreciated that in any of the above mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are tertiarybutyl dimethyl silylchloride, methoxymethyl chloride and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected. The invention is described in the examples given below which are provided by way of illustration only and therefore should not construed to limit the scope of the invention. Example 1 Step (i) Preparation of (S)-2-amino-3-(4-bβnzyIoxyphenyl)propanoic acid of the formula (15)
To a solution of L-tyrosine of the formula (14) (250 g) in 2N NaOH solution (552 ml), copper sulphate solution (172 g of CuSO4 in 600 ml of water) was added and heated at 60 °C for 2 h. The reaction mixture was cooled to room temperature and methanol (2.5 L) and 2N NaOH (83 ml) was added and then benzyl chloride (15 ml) was added drop wise. The reaction mass was allowed to warm to room temperature. The precipitate was filtered and washed to give the title compound as white to off-white solid (260 g, 70 %) (Ref. The practice ofpeptide synthesis, M. Bodansz y & A. Bodanszky pp50).
Step (ii)
Preparation of S(-)-2-hydroxy-3-(4-benzyϊoxyphenyl)propanoic acid of the formula (8a) To a stirred solution of (S)-2-amino-3-(4-benzyloxyphenyl)propanoic acid of the formula (15) (300 g) obtained in step (i) above, in acetone (1.8 L) and dilute H2SO4 (75 ml in 1.2 L of H2O) at 0 °C, a solution of NaNO2 (210 g in 400 ml H2O) was added slowly between 0 °C to 15 °C. After complete addition of NaNO2 the reaction mixture was maintained below 25 °C for a period of 3 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was extracted with ethyl acetate. The organic extracts were concentrated and the residue was purified by washing with diisopropyl ether to give the title compound of the formula (8a) as off white to yellowish solid (159 g, 52.8 %).
Step (iii)
Preparation of crude S(-) ethyl 2-ethoxy-3-(4- bβnzyloxypheny!)propanoate of the formula (9) A mixture of S(-)-2-hydroxy-3-(4-benzyloxyphenyl)propanoic acid of the formula (8a) (50 g), potassium carbonate (152 g), diethyl sulfate (113 g), and toluene (750 ml) was taken in a round bottom flask and refluxed for 24 to 36 h. The completion of the reaction was monitored by TLC. After completion of the reaction, water (500 ml) was added and stirred to dissolve inorganic salts. The organic layer was concentrated to yield crude ethyl 2-ethoxy-3-(4- benzyloxyphenyl)propanoate of the formula (9) (56 g, 93 %).
The other compounds of formula (9) are also prepared using the solvents given below following the procedure as described above :
Figure imgf000011_0001
Preparation of S(-) 2-ethoxy-3-(4-benzy!oxyphenyl)propanoic acid the formula (9a)
To a solution of crude S(-) ethyl 2-ethoxy-3-(4-benzyloxyphenyl)propanoate (180 g) of the formula (9) obtained in step (iii), in methanol (900 ml) cooled to 10-20 °C, sodium hydroxide solution (900 ml) was added slowly. The reaction temperature was raised to 25-30 °C and stirred for 4-6 h. Completion of the reaction was monitored by TLC. After completion of the reaction, water (900 ml) was added and extracted with toluene (2 X 900 ml) to remove impurities. Aqueous layer was removed and pH was adjusted to 2 and extracted with toluene (2 X 900 ml). Combined organic layers were washed with water and concentrated to afford the title compound of the formula (9a) (139 g, 84 %).
Step (v)
Preparation of (S)-2-ethoxy-3-(4-benzyϊoxyphenyl)propanoic acid α- methyl benzyl amine salt of the formula (16)
To S(-) 2-ethoxy-3-(4-benzyloxyphenyl)propanoic acid (141 g) the formula (9a) dissolved in ethylacetate (1.4 L), R(+)-α-methylbenzylamine (57 g) was added slowly and stirred for 3-4 h. The precipitated white solid was filtered (recrystalhsed from ethylacetate 1.5 L if required, to the desired purity) to yield pure (S)-2-ethoxy-3-(4-benzyloxyphenyl)propanoic acid α-methyl benzyl amine salt of the formula (16) (125g, 63 %).
The other compounds of formula (16) are also prepared from S(-) 2-ethoxy-3- (4-benzyloxyphenyl)propanoic acid or S(-) 2-methoxy-3-(4- benzyloxyphenyl)propanoic acid using the chiral bases and solvents given below following the procedure as described above :
Figure imgf000012_0001
Figure imgf000013_0001
Step (vi)
Preparation of (S)-methyϊ 2-ethoxy-3-(4-benzyϊoxyphenyl)propanoate of the formula (9)
A mixture of (S)-2-ethoxy-3-(4-benzyloxyphenyl)propanoic acid α-methyl benzyl amine salt " of the formula (16) or (S)-2-ethoxy-3-(4- benzyloxyphenyl)propanoic acid phenyl glycinol salt of the formula (16), (6.7 g) water (70 ml) and toluene (35 ml) was taken in a reaction flask and stirred for 5-10 min. The reaction mass was cooled to 10-15 °C and 25% cold sulfuric acid was added slowly to adjust pH of the reaction mass to 2. Aqueous and organic layers were separated. Aqueous layer was extracted with toluene (35 ml). The combined toluene layers were washed with water (20 ml) and evaporated to yield (S) 2-ethoxy-3-(4-benzyloxyphenyl)propanoic acid the formula (9a) (4 g).
The pure compound of formula (9a) obtained above was dissolved in methanol (35 ml), sulfuric acid (0.4 ml) was added and stirred at refluxing temperature for 12-24 h. Completion of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was cooled to room temperature, diluted with water (35 ml) and extracted with toluene (2 X 35 ml). The combined organic layers were washed with 0.5 % sodium hydroxide solution (30 ml) and water (50 ml) and concentrated to afford pure tile compound of the formula (9) (3.5 g, 83 %).
The other compounds of formula (9) from compounds of formula (9a) are also prepared using the solvents given below following the procedure as described above :
Figure imgf000014_0001
Step (vii)
Preparation of (S)-methyl 2-ethoxy-3-(4-hydroxypheny!)propanoate of
A mixture of (S)-methyl 2-ethoxy-3-(4-benzyloxyphenyl)propanoate of the formula (9) (56 g) in aqueous methanol (300 ml) and slurry of 5% palladium carbon (6 g in 60 ml water) was taken in hydrogenation flask and hydrogenated on Parr shake flask at 60 psi pressure for 6-8 h at room temperature. Completion of the reaction was monitored by TLC. After completion of the reaction, the catalyst was filtered and the filtrate was evaporated to yield tile compound of the formula (1) (39 g, 96 %).
The other compounds of formula (1) are also prepared using the solvents given below following the procedure as described above :
Figure imgf000015_0001
Advantages of the present process
β An efficient synthesis for the production of compounds of formula (I) with high chiral and chemical purity. « The overall yield of the process has been improved.
• Pyrophoirc and exotic reagents like NaH are replaced with simple, inexpensive chemicals such as diethylsulphate and potassium carbonate.

Claims

Claims :
1. An improved process for the preparation 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1)
Figure imgf000017_0001
where R1 represents hydrogen atom or (Cι-C6)alkyl group and R2 represents (Cι-C6)alkyl group which comprises: (i). selectively benzylating L-tyrosine of the formula (14)
Figure imgf000017_0002
using benzyl halide, CuSO4 and sodium hydroxide in a solvent to yield a compound of the formula (15),
Figure imgf000017_0003
(ii). diazotising the compound of the formula (15) using diazotizing agent in the presence of an acidic reagent and an organic solvent to produce compound of the formula (8 a),
Figure imgf000017_0004
(iii). simultaneous etherification and esteriflcation of compound of formula (8a) using alkylating agent in the presence of a base and a solvent to obtain crude compound of formula (9) with ee >90 %
Figure imgf000017_0005
wherein R1 represents hydrogen or lower alkyl group and R2 represents lower alkyl group.,
(iv). hydrolysing the crude compound of formula (9) obtained in step (iii) above in polar solvents using aqueous alkali to produce compound of formula 5 (9a) acid
Figure imgf000018_0001
wherein R1 represents hydrogen or lower alkyl group,
(v). treating the compound of formula (9a) acid where R1 represents hydrogen or lower alkyl group with chiral base in the presence of solvent to l o produce chemically and chirally pure (ee >99 %) salt of formula (16)
Figure imgf000018_0002
where R represents hydrogen or lower alkyl group and X represents chiral bases such as R(+)-α-methylbenzylamine, S(+) phenylglycinol, cinchonidine, ephidrine, N-octylglucaramine or N-methylglucaramine, 15 (vi). if desired, recrystallising the compound of formula (16) obtained above in a solvent to produce highly pure compound of formula (16) where R1 represents hydrogen or lower alkyl group,
(vii). converting the compound of formula (16) defined above using a solvent and an acid to pure compound of formula (9a),
Figure imgf000018_0003
where R1 represents hydrogen or lower alkyl group, (viii). esterifying the pure compound of formula (9a) defined above using alkylating agent in the presence of base or acid or acidic resin to produce pure compound of formula (9)
Figure imgf000019_0001
where R represents hydrogen or lower alkyl group and R represents lower alkyl group and
(ix). debenzylating the compound of formula (9) using solvents in the presence of metal catalysts to yield pure compound of formula (1) where R1 represents hydrogen or lower alkyl group and R represents lower alkyl group.
2., The process as claimed in claim 1, wherein the solvent used in step (i) is selected from aqueous methanol or ethanol.
3. The process as claimed in claims 1 and 2, wherein the diazotizing agent used in step (ii) is selected from sodium nitrite, isoamyl nitrite, potassium nitrite or ammonium nitrite.
4. The process as claimed in claims 1 to 3, wherein the acidic reagent used in step (ii) is selected from acids such as sulfuric acid, HC1 or acetic acid.
5. The process as claimed in claims 1 to 4, wherein the organic solvent used in step (ii) is selected from CHC13, 1,4-dioxane, THF or acetone
6. The process as claimed in claims 1 to 5, wherein the allcylating agent used in ste . (iii) is selected from dimethyl sulfate, diethyl sulfate, methyliodide or ethyliodide.
7. The process as claimed in claims 1 to 6, wherein the solvent used in step (iii) is selected from toluene, benzene, DMF, DMSO or MIBK.
8. The process as claimed in claims 1 to 7, wherein the base used in step (iii) is selected from sodium carbonate, potassium carbonate, sodium methoxide or sodium hydride.
9. The process as claimed in claims 1 to 8, wherein the polar solvent used in step (iv) is selected from methanol, ethanol, propanol, isopropanol, acetone or' methyl ethyl ketone.
10. The process as claimed in claims 1 to 9, wherein the alkali used in step (iv) is selected from sodium hydroxide or potassium hydroxide.
11. The process as claimed in claims 1 to 10, wherein the chiral base used in step (v) is selected from R(+)α-methylbenzylamine, S(+)~phenylglycinol, cinchonidine, ephidrine, N-octylglucaramine or N-methylglucaramine.
12. The process as claimed in claims 1 to 11, wherein the solvent used in step (v) is selected from methyl acetate, ethyl acetate, ethyl propanoate, n- butylacetate, methanol, ethanol, propanol, isopropanol, acetone, methyl isobutyl ketone or acetonitrile.
13. The process as claimed in claims 1 to 12, wherein the recrystallization in step (vi) is effected using solvent such as methyl acetate, ethyl acetate, ethyl propanoate, n-butylacetate, methanol, ethanol, propanol, isopropanol, acetone, methyl isobutyl ketone or acetonitrile.
14. The process as claimed in claims 1 to 13, wherein the acid used in step (vii) is selected from hydrochloric acid or sulfuric acid.
15. The process as claimed in claims 1 to 14, wherein the solvent used in step (vii) is selected from toluene, xylene, ethyl acetate, diethyl ether or methyl tertiary butyl ether.
16. The process as claimed in claims .1 to 15, wherein the allcylating agent used in step (viii) is selected from methanol, ethanol, propanol, isopropanol, butanol, dimethyl sulfate or diethyl sulfate.
17. The process as claimed in claims 1 to 16, wherein the acid used in step (viii) is selected from sulfuric acid or hydrochloric acid.
18. The process as claimed in claims 1 to 17, wherein the acidic resin used in step (viii) is selected from amberlite or amberlist.
19. The process as claimed in claims 1 to 18, wherein the base used in step (viii) is selected from potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate or organic bases such as alkoxides like sodium ethoxide, potassium tertiary butoxide or triethyl amine.
20. The process as claimed in claims 1 to 19, wherein the solvent used in step (ix) is selected from THF, aqueous acetic acid, ethyl acetate, aqueous or non aqueous (Cι-C6) alcohols such as methanol, ethanol, propanol or isopropanol.
21. The process as claimed in claims 1 to 20, wherein the metal catalysts used in step (ix) is Pd/C.
22. An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives of the formula (1) substantially as herein described with reference to the Examples.
PCT/IB2001/001699 2000-09-22 2001-09-17 Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives WO2002024625A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001286163A AU2001286163A1 (en) 2000-09-22 2001-09-17 An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN795/MAS/2000 2000-09-22
IN795MA2000 2000-09-22
US09/836,559 2001-04-17
US09/836,559 US6559335B2 (en) 2000-09-22 2001-04-17 Process for the preparation of 3-aryl-2-hydroxy propanoic acid

Publications (2)

Publication Number Publication Date
WO2002024625A2 true WO2002024625A2 (en) 2002-03-28
WO2002024625A3 WO2002024625A3 (en) 2002-06-27

Family

ID=26324896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001699 WO2002024625A2 (en) 2000-09-22 2001-09-17 Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives

Country Status (2)

Country Link
AU (1) AU2001286163A1 (en)
WO (1) WO2002024625A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019152A2 (en) * 2003-06-06 2005-03-03 Cadila Healthcare Limited Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution
EP1619179A1 (en) * 2004-06-17 2006-01-25 Ajinomoto Co., Inc. Production method of O-substituted tyrosine compound
WO2014181362A1 (en) 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research A process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds
WO2014195967A3 (en) * 2013-05-30 2015-03-26 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
US9656954B2 (en) 2013-07-05 2017-05-23 Cadila Healthcare Limited Synergistic compositions
US9783495B2 (en) 2011-01-31 2017-10-10 Cadila Healthcare Limited Treatment for lipodystrophy
US9814697B2 (en) 2013-04-22 2017-11-14 Cadila Healthcare Limited Composition for nonalcoholic fatty liver disease (NAFLD)
US10098868B2 (en) 2013-07-25 2018-10-16 Cadila Healthcare Limited Formula comprising a hypolipidemic agent
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US11433050B2 (en) 2016-12-09 2022-09-06 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026200A1 (en) * 1998-10-29 2000-05-11 Dr. Reddy's Research Foundation An improved process for the preparation of new antidiabetic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026200A1 (en) * 1998-10-29 2000-05-11 Dr. Reddy's Research Foundation An improved process for the preparation of new antidiabetic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAIGH D ET AL: "NON-THIAZOLIDINEDIONE ANTIHYPERGLYCAEMIC AGENTS. PART 3: THE EFFECTS OF STEREOCHEMISTRY ON THE POTENCY OF ALPHA-METHOXY-BETA-PHENYLPROPAN OIC ACIDS" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, 1999, pages 821-830, XP000995637 ISSN: 0968-0896 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019152A3 (en) * 2003-06-06 2005-08-11 Cadila Healthcare Ltd Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution
WO2005019152A2 (en) * 2003-06-06 2005-03-03 Cadila Healthcare Limited Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution
EP1619179A1 (en) * 2004-06-17 2006-01-25 Ajinomoto Co., Inc. Production method of O-substituted tyrosine compound
US7217835B2 (en) 2004-06-17 2007-05-15 Ajinomoto Co., Inc. Production method of O-substituted tyrosine compound
US9783495B2 (en) 2011-01-31 2017-10-10 Cadila Healthcare Limited Treatment for lipodystrophy
US10017470B2 (en) 2011-01-31 2018-07-10 Cadila Healthcare Limited Treatment for lipodystrophy
US9814697B2 (en) 2013-04-22 2017-11-14 Cadila Healthcare Limited Composition for nonalcoholic fatty liver disease (NAFLD)
WO2014181362A1 (en) 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research A process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds
US9550719B2 (en) 2013-05-09 2017-01-24 Council Of Scientific And Industrial Research Process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds
WO2014195967A3 (en) * 2013-05-30 2015-03-26 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
US10435363B2 (en) 2013-05-30 2019-10-08 Cadila Healthcare Limited Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
US9656954B2 (en) 2013-07-05 2017-05-23 Cadila Healthcare Limited Synergistic compositions
US9957230B2 (en) 2013-07-05 2018-05-01 Cadila Healthcare Limited Synergistic compositions
US10315993B2 (en) 2013-07-05 2019-06-11 Cadila Healthcare Limited Synergistic compositions
US10098868B2 (en) 2013-07-25 2018-10-16 Cadila Healthcare Limited Formula comprising a hypolipidemic agent
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US11433050B2 (en) 2016-12-09 2022-09-06 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
US11872209B2 (en) 2016-12-09 2024-01-16 Zydus Lifesciences Limited Treatment for primary biliary cholangitis

Also Published As

Publication number Publication date
AU2001286163A1 (en) 2002-04-02
WO2002024625A3 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
US8101804B2 (en) Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol
WO2002024625A2 (en) Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
US7223881B2 (en) Process for the preparation of new antidiabetic agents
US6559335B2 (en) Process for the preparation of 3-aryl-2-hydroxy propanoic acid
GB2098981A (en) Preparataion of d-2-(6-methoxy-2-naphthyl) propionic acid
WO2007026373A2 (en) Process for preparing rivastigmine
WO2008078350A2 (en) Process for the preparation of fluorophenylacetic acids and derivatives thereof
EP1397335B1 (en) Resolution process for (r)-(-)-2-hydroxy-2-(2-chlorophenyl)acetic acid
WO2007125542A2 (en) A process for preparation of adapalene
US7470809B2 (en) Process for the production of [2-(4-fluoro-benzyl)-phenyl]-acetic acid
US4760145A (en) Certain 6,7-methylene dioxydihydro or tetrahydro-isoquinoline derivatives
EP0880518B1 (en) A process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
US6531596B1 (en) Process for the preparation of new antidiabetic agents
CN113072471B (en) Lifeiste intermediate and preparation method thereof
US7230129B2 (en) Process for the preparation of optically pure isomers of 2-(4-hydroxy phenoxy)-2-methyl-butyric acid methyl ester
AU2004266204A1 (en) Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution
JP3144920B2 (en) α-Acylaminoketone derivatives, production method thereof and use thereof
EP1789375B1 (en) Process for the production of [2-(4-fluoro-benzyl)-phenyl]-acetic acid
WO2024028999A1 (en) Method for producing n-[4-methylaminobenzoyl]-l-glutamic acid diethyl ester
JP3144921B2 (en) Benzyl ester derivative and method for producing the same
CN114507184A (en) Synthesis method and application of 1-methylhexahydroazepin-4-one hydrochloride
JP2006076911A (en) Quaternary ammonium salt having spiro-chirality, method for producing the same and asymmetric catalytic reaction using the ammonium salt
KR20090025686A (en) New 2-oxoimidazolidine derivate and process for preparation thereof
WO1997017071A1 (en) Stereoselective synthesis of endothelin receptor antagonists
WO2003008397A1 (en) An improved process for the preparation of antidiabetic phenoxazine compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP